Last year, the Structural Antibody Database (SAbDab) listed a record-breaking 894 new antibody structures, driven in no small part by the continued efforts of the researchers to understand SARS-CoV-2.
In this blog post I wanted to highlight the major driving force behind this curve – the huge increase in cryo electron microscopy (cryoEM) data – and the implications of this for the field of structure-based antibody informatics.
Continue readingIn June, after I finish my PhD, I will be joining Chemify, a new startup based in Glasgow that aims to make chemical synthesis universally accessible, reproducible and fully automated using AI and robotics. After previously talking about “Why you should care about startups as a researcher” and a quick guide on “Commercialising your research: Where to start?” on this blog, I have now joined a science-based startup fresh out of university myself.
Chemify is a spinout from the University of Glasgow originating from the group of Prof. Lee Cronin. The core of the technology is the chemical programming language χDL (pronounced “chi DL”) that, in combination with a natural language processing AI that reads and understands chemical synthesis procedures, can be used to plan and autonomously executed chemical reactions on robotic hardware. The Cronin group has also already build the modular robotic hardware needed to carry out almost any chemical reaction, the “Chemputer”. Due to the flexibility of both the Chemputer and the χDL language, Chemify has already shown that the applications go way beyond simple synthesis and can be applied to drug formulation, the discovery of new materials or the optimisation of reaction conditions.
Armed with this transformational software and hardware, Chemify is now fully operational and is hiring exceptional talent into their labs in Glasgow. I am excited to see how smart, AI-driven automation techniques like Chemify will change how small scale chemical synthesis and chemical discovery more broadly is done in the future. I’m super excited to be part of the journey.
Molecular docking helps us understand how small-molecules interact with proteins. This is especially useful in early drug development stages such as target identification and compound screening. Quick and accurate docking software allows researchers to focus their attention on a smaller set of lead molecules for further testing. Traditionally, docking software has employed first principles from physics and chemistry. Recently, deep learning has become all the rage for molecular docking, maybe motivated by the successful application of deep learning to molecular folding.
EquiBind is a deep learning unconstrained docking method which models a fixed receptor and a ligand with selected rotatable bonds. It predicts the binding pocket and the ligand’s conformation within the pocket in one go. Under the hood, EquiBind employs two great ideas from a recent ICLR 2022 Paper: a SE3-invariant graph neural network based architecture and the idea to generate fixed sets of matching key points to define a rotation and translation between receptor and ligand. In addition, the authors innovate a fast method to project a deformed ligand onto the space spanned by the rotatable bonds of a pre-generated ligand conformation.
Continue reading“Cheminformatics is hard.”
— Paul Finn
I would add: “Chemistry is nuanced”… Just as there are many different ways of drawing the same molecule, SMILES is flexible enough to allow us to write the same molecule in different ways. While canonical SMILES can resolve this problem, we sometimes have different problem. In some situations, e.g., in machine learning, we need to map all these variants back to the same molecule. We also need to make sure we clean up our input molecules and eliminate invalid or incomplete structures.
Sometimes, a chemical supplier or compound vendor provides a salt of the compound, e.g., sodium acetate, but all we care about is the organic anion, i.e., the acetate. Very often, our models are built on the assumption we have only one molecule as input—but a salt will appear as two molecules (the sodium ion and the acetate ion). We might also have been given just the negatively-charged acetate instead of the neutral acetic acid.
Another important chemical phenomenon exists where apparently different molecules with identical heavy atoms and a nearby hydrogen can be easily interconverted: tautomers. By moving just one hydrogen atom and exchanging adjacent bond orders, the molecule can convert from one form to another. Usually, one tautomeric form is most stable. Warfarin, a blood-thinning drug, can exist in solution in 40 distinct tautomeric forms. A famous example is keto-enol tautomerism: for example, ethenol (not ethanol) can interconvert with the ketone form. When one form is more stable than the other form(s), we need to make sure we convert the less stable form(s) into the most stable form. Ethenol, a.k.a. vinyl alcohol, (SMILES: ‘C=CO[H]’), will be more stable when it is in the ketone form (SMILES: ‘CC(=O)([H])’):
from IPython.display import SVG # to use Scalar Vector Graphics (SVG) not bitmaps, for cleaner lines
import rdkit
from rdkit import Chem
from rdkit.Chem import AllChem
from rdkit.Chem import Draw # to draw molecules
from rdkit.Chem.Draw import IPythonConsole # to draw inline in iPython
from rdkit.Chem import rdDepictor # to generate 2D depictions of molecules
from rdkit.Chem.Draw import rdMolDraw2D # to draw 2D molecules using vectors
AllChem.ReactionFromSmarts('[C:1]-[C:2](-[O:3]-[H:4])>>[C:1]-[C:2](=[O:3])(-[H:4])')
Tobias and I recently gave a talk at the OPIG retreat on tips for using PyTorch. For this we created a tutorial on Google Colab notebook (link can be found here). I remember rambling about the advantages of implementing your own models against using other peoples code. Well If I convinced you, einops is for you!!
Basically, einops lets you perform operations on tensors using the Einstein Notation. This package comes with a number of advantages a few of which I will try and summarise here:
Continue readingWe have reached the era of design, not just ‘hunting’. Particularly exciting to me is the de novo design of proteins, which have a wide and ever increasing range of applications from therapeutics to consumer products, biomanufacturing to biomaterials. Protein design has been a) enabled by decades of research that contributed to our understanding of protein sequence, structure & function and b) accelerated by computational advances – capturing the information we have learned from proteins and representing it for computers and machine learning algorithms.
In this blog post, I will discuss three key methodological considerations for computational protein design:
Despite some of their technical issues, graph neural networks (GNNs) are quickly being adopted as one of the state-of-the-art methods for molecular property prediction. The differentiable extraction of molecular features from low-level molecular graphs has become a viable (although not always superior) alternative to classical molecular representation techniques such as Morgan fingerprints and molecular descriptor vectors.
But molecular data usually comes in the sequential form of labeled SMILES strings. It is not obvious for beginners how to optimally transform a SMILES string into a structured molecular graph object that can be used as an input for a GNN. In this post, we show how to convert a SMILES string into a molecular graph object which can subsequently be used for graph-based machine learning. We do so within the framework of Pytorch Geometric which currently is one of the best and most commonly used Python-based GNN-libraries.
We divide our task into three high-level steps:
I was invited to speak at the Antibody Engineering and Therapeutics Conference (presenting mine and Matt’s recently published epitope profiling paper), in San Diego (December 12th – 16th). Unfortunately, the pandemic had other ideas so I decided not to travel but luckily the conference was hybrid.
The conference included 1 day of pre-conference workshops and 4 days of presentations from academic and industry, with livestreaming of the initial keynotes (including one from Charlotte). Remaining talks were recorded and made available after the conference. I’ve highlighted a few of my favourite talks and conference themes, with links to papers where available.
Naturally, a lot of the presented research related to covid-19. I was speaking in the ‘Antibody Repertoires and Covid-19’ session, where there were interesting presentations from Professor Eline Luning Prak from the University of Pennsylvania and Elaine Chen from Vanderbilt University analysing antibody responses in covid-recovered individuals, and comparing vaccine responses in covid-recovered vs covid-naiive individuals. Other talks around SARS-CoV-2 vaccines included Dr Laura Walker from Adimab/Adagio Therapeutics comparing BCR repertoire responses to different types of vaccinations, and the effect of using different booster types.
Continue readingLast month, I was fortunate enough to be able to attend (in person!) and present at the Festival of Biologics European Antibody Congress (9-11 November, 2021) in Basel, Switzerland. The Festival of Biologics is an annual conference, which brings together researchers from industry and academia. It was an excellent opportunity to learn about exciting research and meet people working in the antibody development field.
Here are some of my highlights from the European Antibody Congress, with a focus on antibody design and engineering:
Continue readingIn our latest immunoinformatics review, OPIG has teamed up with experienced antibody consultant Dr. Anthony Rees to outline the evidence for BCR/antibody repertoire convergence on common epitopes post-pathogen exposure, and all the ways we can go about detecting it from repertoire gene sequencing data. We highlight the new advances in the repertoire functional analysis field, including the role for OPIG’s latest tools for structure-aware antibody analytics: Structural Annotation of AntiBody repertoires+ (SAAB+), Paratyping, Ab-Ligity, Repertoire Structural Profiling & Structural Profiling of Antibodies to Cluster by Epitope (‘SPACE’).
Continue reading